In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape
Symptoms often relate to meal size, fat content, and eating pace , and many patients improve with time and behavioral adjustments
It also appears to play a role in fat metabolism, though the exact mechanisms are still being elucidated in clinical research
The mixture was vortexed for 10 s and kept on ice for 3 min
The compound is being evaluated in the Phase 3 REDEFINE program, including REDEFINE 1 in adults with overweight or obesity without diabetes and REDEFINE 2 in adults with overweight or obesity and type 2 diabetes [5][6]
The FDA has raised safety concerns about compounded semaglutide and tirzepatide products
